Collaboration and Licensing Revenue (Tables)

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the three and six months ended June 30, 2016 and 2015.

	Three Months Ended June 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	922	$	6,048	$	6,970
Oragenics, Inc.	261		246		507
Fibrocell Science, Inc.	605		789		1,394
Genopaver, LLC	68		1,569		1,637
S & I Ophthalmic, LLC	—		2,358		2,358
OvaXon, LLC	—		808		808
Intrexon Energy Partners, LLC	625		3,587		4,212
Persea Bio, LLC	125		206		331
Ares Trading S.A.	1,597		621		2,218
Thrive Agrobiotics, Inc.	46		404		450
Intrexon Energy Partners II, LLC	500		394		894
Exotech Bio, Inc.	139		—		139
Relieve Genetics, Inc.	120		230		350
Intrexon T1D Partners, LLC	278		32		310
Other	2,769		2,134		4,903
Total	$	8,055	$	19,426	$	27,481

	Three Months Ended June 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	644	$	4,606	$	5,250
Oragenics, Inc.	307		68		375
Fibrocell Science, Inc.	448		1,470		1,918
Genopaver, LLC	68		867		935
S & I Ophthalmic, LLC	—		890		890
OvaXon, LLC	—		662		662
Intrexon Energy Partners, LLC	625		2,731		3,356
Persea Bio, LLC	125		141		266
Ares Trading S.A.	739		—		739
Other	747		2,043		2,790
Total	$	3,703	$	13,478	$	17,181

	Six Months Ended June 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,844	$	12,107	$	13,951
Oragenics, Inc.	524		789		1,313
Fibrocell Science, Inc.	1,210		2,041		3,251
Genopaver, LLC	137		3,078		3,215
S & I Ophthalmic, LLC	—		3,544		3,544
OvaXon, LLC	—		1,502		1,502
Intrexon Energy Partners, LLC	1,250		6,950		8,200
Persea Bio, LLC	250		405		655
Ares Trading S.A.	3,194		1,429		4,623
Thrive Agrobiotics, Inc.	92		792		884
Intrexon Energy Partners II, LLC	1,000		444		1,444
Exotech Bio, Inc.	139		—		139
Relieve Genetics, Inc.	120		230		350
Intrexon T1D Partners, LLC	278		32		310
Other	3,789		4,384		8,173
Total	$	13,827	$	37,727	$	51,554

	Six Months Ended June 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,288	$	7,763	$	9,051
Oragenics, Inc.	569		76		645
Fibrocell Science, Inc.	896		3,183		4,079
Genopaver, LLC	137		1,467		1,604
S & I Ophthalmic, LLC	—		1,645		1,645
OvaXon, LLC	—		1,306		1,306
Intrexon Energy Partners, LLC	1,250		4,916		6,166
Persea Bio, LLC	250		256		506
Ares Trading S.A.	739		—		739
Other	1,605		4,618		6,223
Total	$	6,734	$	25,230	$	31,964

Summary of Deferred Revenue

Deferred revenue consists of the following:

	June 30, 2016		December 31, 2015
Upfront and milestone payments	$	310,937	$	181,331
Prepaid research and development services	8,122		10,938
Prepaid product and service revenues	5,471		4,759
Other	709		701
Total	$	325,239	$	197,729
Current portion of deferred revenue	$	53,863	$	35,366
Long-term portion of deferred revenue	271,376		162,363
Total	$	325,239	$	197,729

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:

	June 30, 2016		December 31, 2015
ZIOPHARM Oncology, Inc.	$	148,494	$	30,338
Oragenics, Inc.	8,289		8,813
Fibrocell Science, Inc.	20,235		21,445
Genopaver, LLC	2,113		2,250
Intrexon Energy Partners, LLC	19,375		20,625
Persea Bio, LLC	4,250		4,500
Ares Trading S.A.	50,373		53,567
Thrive Agrobiotics, Inc.	1,529		1,621
Intrexon Energy Partners II, LLC	16,833		17,833
Exotech Bio, Inc.	4,861		—
Relieve Genetics, Inc.	4,213		—
Intrexon T1D Partners, LLC	9,564		—
AD Skincare, Inc.	4,333		—
Other	16,475		20,339
Total	$	310,937	$	181,331